Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmaceutical companies clinical trials

The first extensively documented British case, in 1988, was that of Dr Uzair Siddiqui, a psychiatrist in the city of Durham (Anon. 1988). He was found by an astute pharmaceutical company clinical trial monitor to have invented some of the laboratory data for most of the patients purported to have taken part in the trial and to have invented one complete patient. The laboratories used for this... [Pg.442]

Even on a relatively small subset of reused data, it is possible to license old medicines for new therapeutic applications and greatly reduce the costs of clinical development—many of these reused medicines have already passed muster for pharmacokinetic safety, so smaller-scale clinical trials are possible, saving considerable money (e.g., Arakis—soon to become Sosei). Even Sildenafil may have new indications [39]. There are huge potential reserves of information to mine in each and every large pharmaceutical company ... [Pg.180]

The synthesis of (+)-discodermolide shown in Scheme 13.74 was developed in the laboratories of the Novartis Pharmaceutical Company and was designed to provide sufficient material for initial clinical trials. The synthesis is largely based on the one... [Pg.1241]

Contracting out of activities previously only conducted in-house is already becoming quite common and will probably continue to develop. In the past a so-called full-service pharmaceutical company took direct responsibility for all the activities required for the formulation, manufacture, quality control, and regulatory approval of its drug products. Nowadays the use of specialist contract houses to perform activities such as formulation, analytical methods development, manufacture of clinical trials supplies, supervision of the assembly of an NDA, postmarketing surveillance, and even troubleshooting may be contracted for even by some of the largest companies. [Pg.820]

Research is also strongly influenced by the admittedly legitimate interests of the pharmaceutical industry examples of this include contract clauses reserving copyright, the initial selection of researchers and topics, and the recent consolidation of the position of companies specializing in clinical trials (to the detriment of academic centres). Frequently there is a conflict of interests between social welfare and private welfare that does not necessarily amount to fraud or malpractice, but which should be made public - through... [Pg.173]

To date, three pharmaceutical companies have entered clinical trials with PHD inhibitors for the treatment of anemia with the most advanced being FG-2216. In clinical studies, compound 2 (likely FG-2216) showed a dose- and time-dependent elevation of plasma erythropoietin after oral administration [66]. Healthy volunteers were orally administered various doses of compound 2 and serum erythropoietin (EPO) concentrations were measured at various times. Compound 2 increased serum EPO levels in a dose-dependent manner and, following administration of the 20 mg/kg dose, a 5-fold increase of EPO levels was observed after 12 h. In the same patent application, the effect of 2 on anemic predialysis patients with no previous rh-EPO exposure was also disclosed. Patients were treated with 2 three times/week for 4 weeks (no dose reported) and the hemoglobin levels were assessed on day 42. The patients who received treatment showed a mean increase in hemoglobin of 1.9 g/dL from baseline values, whereas subjects who received placebo showed a mean decrease of 0.35 g/dL from baseline levels. These data suggest for the first time that an oral PHD inhibitor could be effective for the treatment of anemia. [Pg.136]

Hydroxamic acid derivatives, which belong to a new class of NO donors, have been shown to inhibit the matrix metalloproteinases (MMPs) [112]. MMPs are a family of zinc-dependent endopeptidases, which play a critical role in multiple steps in the metastatic cascade and facilitate neoangiogenesis. Numerous hydroxamic acids, such as marimastat, have been developed, that bind the zinc atom in the active catalytic domain of MMPs. During a randomized Phase III trial, comparing marimastat with placebo in patients with metastatic breast cancer, marimastat was not associated with an improvement in progression-free survival or overall survival. Other studies also indicated no benefit for MMP inhibitors when used either in combination with chemotherapy or sequentially after first-line chemotherapy in a variety of cancers [113]. Currently, many pharmaceutical companies have suspended clinical development of this kind of agent. [Pg.20]

MK-0859 is another CETP inhibitor that has advanced into Phase II clinical trials [79,80]. In addition, a number of novel inhibitors of CETP have emerged from different pharmaceutical companies but their current status is unclear [81-88]. [Pg.184]


See other pages where Pharmaceutical companies clinical trials is mentioned: [Pg.232]    [Pg.299]    [Pg.207]    [Pg.401]    [Pg.332]    [Pg.3]    [Pg.88]    [Pg.122]    [Pg.296]    [Pg.428]    [Pg.429]    [Pg.531]    [Pg.579]    [Pg.756]    [Pg.26]    [Pg.15]    [Pg.2]    [Pg.3]    [Pg.9]    [Pg.198]    [Pg.291]    [Pg.106]    [Pg.740]    [Pg.38]    [Pg.39]    [Pg.83]    [Pg.43]    [Pg.201]    [Pg.386]    [Pg.106]    [Pg.904]    [Pg.129]    [Pg.135]    [Pg.180]    [Pg.229]    [Pg.229]    [Pg.230]    [Pg.278]    [Pg.325]    [Pg.329]    [Pg.29]    [Pg.267]   


SEARCH



Clinical trials, pharmaceuticals

Pharmaceutical companies

Pharmaceutical trials

Pharmaceuticals clinical

© 2024 chempedia.info